Pfizer
FDA approves Pfizer’s abuse-deterrent opioid painkiller
August 22, 2016Sales and Marketing FDA, Pfizer, abuse deterrent, abuse-deterrent, approval, opioid, troxyca
Pfizer has announced that the US FDA has approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for the …
Pfizer’s Xalkori price drop secures NICE recommendation
August 18, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Pfizer, Xalkori, crizotinib, lung cancer
The National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Xalkori (crizotinib) as a treatment for lung cancer, …
MSD joins Medivation race, says reports
August 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing MSD, Medivation, Merck, Pfizer, Sanofi, Xtandi, takeover
MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology …
Revenue rises at Pfizer as Ibrance and Xeljanz beat sales expectations
August 2, 2016Research and Development, Sales and Marketing 2016, Pfizer, Prevnar, Q2, Xeljanz, ibrance, results
Pfizer has published its Q2 results, which show revenues rising 11% with new drugs helping to drive the growth and …
Pfizer expands gene therapy operations with acquisition of Bamboo Therapeutics
August 2, 2016Manufacturing and Production, Research and Development Pfizer, acquisition, bamboo therapeutics, gene therapy
Pfizer has announced that it has acquired gene therapy biotech Bamboo Therapeutics for an initial $150 million, with potential milestone …
Ulcerative colitis treatment Xeljanz records positive top-line results in Phase III trial
July 29, 2016Medical Communications, Research and Development Pfizer, Xeljanz, tofacitinib, ulcerative colitis
Pfizer has announced positive top-line results from oral clinical trials for tofacitinib in ulcerative colitis (Octave) sustain, the third Phase …
Pfizer and Spark Therapeutics granted FDA breakthrough designation for haemophilia drug
July 22, 2016Medical Communications, Research and Development FDA, Pfizer, Spark Therapeutics, haemophilia B, spk-9001
Pfizer and Spark Therapeutics have announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation …
Pfizer announces strong Phase III results for atopic dermatitis drug
July 14, 2016Research and Development Pfizer, anacor, atopic dermatitis, crisaborole, eczema
Pfizer (NYSE: PFE) has announced positive results from two pivotal Phase III studies for crisaborole in the treatment of mild …
Pfizer gets approval expansion from FDA for pneumonia vaccine
July 13, 2016Research and Development, Sales and Marketing FDA, Pfizer, Prevnar 13, adults, approval
The US Food and Drug Administration (FDA) has issued an expanded approval for Pfizer’s pneumococcal pneumonia vaccine Prevnar 13 to …
AstraZeneca mulling a $10-billion bid for Medivation – report
July 12, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Celgene, Medivation, Pfizer, Xtandi, cancer drug, merger and acquisition
Anglo Swedish drug firm AstraZeneca (LSE: AZN) is considering a $10-billion takeover bid for Medivation (Nasdaq: MDVN), according to reports. …
Pfizer says its Sutent meets primary endpoint in Phase III trials for kidney cancer recurrence
July 11, 2016Research and Development, Sales and Marketing Kidney cancer, Pfizer, Stutent, drug trial
US pharma giant Pfizer (NYSE: PFE) said late-stage trials for its Sutent (sunitinib) met its primary endpoint as a treatment …
Pfizer’s blood cancer drug first to be reappraised from Cancer Drug Fund
July 7, 2016Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Pfizer, blood cancer, bosulif
The National Institute for Health and Care Excellence (Nice) recommended US pharma giant Pfizer’s (NYSE: PFE) Bosulif (bosutinib) to treat …
Merck and Pfizer begin Phase III trials for avelumab in ovarian cancer
July 6, 2016Research and Development Merck, Pfizer, avelumab
Merck (KGaA, Darmstadt) and Pfizer (NYSE: PFE) have announced the initiation of the first Phase III study of investigational compound, …
Pfizer to invest about $350 million in China biotech facility, first in Asia
June 29, 2016Research and Development, Sales and Marketing Biotech Plant, China, Pfizer, research
US pharma giant Pfizer (NYSE: PFE) said it will invest about $350 million for a global biotechnology center in the …
Pfizer breaks ground on new $200 million biologics facility
June 17, 2016Medical Communications, Research and Development Manufacturing Facility, Pfizer
Pfizer (NYSE: PFE) has broken ground on a new $200 million biologics clinical manufacturing facility in Andover, Massachusetts. This expansion …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
